Standard carotid endarterectomy versus carotid artery stenting with closed-cell stent design and distal embolic protection: does the age matter?
Date
2019Author
Peluso, Andrea
Turchino, Davide
Petrone, Alessio
Giribono, Anna Maria
Bracale, Renata
Del Guercio, Luca
Bracale, Umberto Marcello
Metadata
Show full item recordAbstract
Carotid artery endarterectomy (CEA) is
considered the gold standard for treatment of
symptomatic and asymptomatic carotid disease.
Carotid artery stenting (CAS) is a less invasive
approach and therefore could be considered a viable
alternative to CEA, especially in high-risk patients or
those with relative contraindications to CEA (i.e.
actinic stenosis, post-CEA restenosis, previous neck
or tracheostomy surgery, contralateral laryngeal
nerve paralysis, etc.).
Methods – The aim of this study is to evaluate the
short- and medium-term outcomes of CAS
performed with a single type of closed-cell stent
design and distal filter protection by comparing the
procedure with CEA based upon 3 endpoints: overall
survival rate, stroke free survival rate and restenosis
free survival rate.
The same endpoints were also evaluated in 2
different age groups, more and less than 70 years, to
show possible age-based differences on outcomes.
Among 105 patients (77 males, 28 females), 74 were
submitted to CEA and 31 were subject to CAS.
In all cases the same self-expanding stent with
closed-cell design (XACT Carotid Stent, Abbott
Vascular) and the same distal embolic protection
device (Emboshield NAV, Abbott Vascular) were
employed.
Results – At 12 months, no statistically significant
difference was observed in overall survival rates
(CEA 93.2% vs CAS 93.5%, p=0.967) and restenosis
free survival rates (CEA 94.5% vs CAS 96.8%,
p=0.662).
An increased stroke free survival rate was observed
in the CEA group when compared to the CAS group
(CEA 100.0% vs CAS 93.5%, p=0.028).
The age-based endpoints didn’t show any significant
difference.
Conclusion - These results suggest that CEA still
remains the gold standard of treatment for carotid
stenosis given its greater efficacy in the prevention
of stroke CAS. However, CAS could be considered
as an alternative treatment to CEA to be used in
select cases only.